Arcus Biosciences (RCUS) Tops Q2 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q2 EPS of ($1.04), $0.06 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $29 million versus the consensus estimate of $31.81 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• UBS Reiterates Neutral Rating on Buckle, Inc. (BKE)
• What Delta’s report tells investors in American and United